Definition
An indirect agonist is a pharmacological agent that produces a biological response by increasing the concentration, release, or activity of an endogenous agonist rather than by binding directly to and activating the target receptor itself. The effect of an indirect agonist depends on the presence and availability of the natural ligand and the integrity of the endogenous signaling pathways.
Mechanisms of Action
| Mechanistic pathway | Description | Representative examples |
|---|---|---|
| Inhibition of neurotransmitter reuptake | Blocks transporters that remove the endogenous agonist from the synaptic cleft, prolonging its action. | Cocaine (dopamine, norepinephrine, serotonin reuptake inhibition); selective serotonin reuptake inhibitors (SSRIs) for serotonin. |
| Inhibition of metabolic degradation | Prevents enzymatic breakdown of the endogenous agonist, raising its extracellular concentration. | Monoamine oxidase inhibitors (MAOIs) that prevent degradation of serotonin, norepinephrine, and dopamine. |
| Facilitation of neurotransmitter release | Enhances the exocytotic release of the endogenous agonist from presynaptic terminals. | Amphetamines stimulate release of norepinephrine, dopamine, and serotonin. |
| Modulation of storage or synthesis | Increases synthesis or vesicular storage of the agonist, indirectly raising its availability. | L‑DOPA (precursor that boosts dopamine synthesis). |
| Allosteric modulation that enhances endogenous ligand efficacy | Binds to a distinct site on the receptor, increasing the response to the natural agonist without activating the receptor alone. While technically “positive allosteric modulators,” they are sometimes described as indirect agonists. | Benzodiazepines at the GABA_A receptor. |
Pharmacological Classification
Indirect agonists are usually grouped under “indirect-acting agents” in pharmacology texts, contrasting them with direct agonists (which bind to the receptor's orthosteric site) and antagonists (which block receptor activation).
Clinical Applications
- Psychiatry: MAOIs and SSRIs are indirect agonists used in the treatment of depressive disorders by augmenting serotonergic signaling.
- Neurology: L‑DOPA is employed in Parkinson’s disease to increase central dopamine levels.
- Substance use disorders: Understanding the indirect agonist properties of stimulants (e.g., amphetamines) informs both therapeutic use (e.g., ADHD treatment) and abuse potential.
- Cardiovascular medicine: Certain indirect adrenergic agents (e.g., ephedrine) raise norepinephrine levels to increase cardiac output in hypotensive states.
Advantages and Limitations
| Advantage | Limitation |
|---|---|
| May produce a more physiologic pattern of receptor activation because the endogenous agonist is released in a spatially and temporally regulated manner. | Efficacy is contingent on intact endogenous synthesis and release mechanisms; depleted stores limit the drug’s effect. |
| Often have a broader spectrum of activity (e.g., affecting multiple monoamines), useful in complex disorders. | Higher risk of indirect effects such as hypertensive crises with MAOIs when combined with dietary tyramine. |
| Can exhibit ceiling effects linked to the maximal amount of endogenous ligand available, reducing overdose severity in some cases. | Potential for paradoxical responses if feedback mechanisms down‑regulate endogenous ligand production. |
Research and Development
Current investigations explore selective indirect agonists that preferentially target discrete neuronal circuits, aiming to maximize therapeutic benefit while minimizing systemic side effects. Examples include novel norepinephrine reuptake inhibitors with limited serotonergic activity for attention‑deficit/hyperactivity disorder (ADHD).
See also
- Direct agonist
- Positive allosteric modulator
- Reuptake inhibitor
- Enzyme inhibitor (pharmacology)
- Neurotransmitter release modulator
References
- Rang, H. P., Dale, M. M., Ritter, J. M., & Flower, R. J. (2022). Rang & Dale’s Pharmacology (9th ed.). Elsevier.
- Goodman, L. S., & Gilman, A. (2021). The Pharmacological Basis of Therapeutics (14th ed.). McGraw‑Hill.
- Stahl, S. M. (2020). Stahl’s Essential Psychopharmacology (5th ed.). Cambridge University Press.
- Kula, T., & Novotny, M. (2023). “Indirect agonism at monoamine transporters: therapeutic implications.” Pharmacology & Therapeutics, 240, 108521.
This entry reflects current understanding as documented in peer‑reviewed pharmacology literature.
